Fatty Liver Disease in Canada: 7 Million Affected — Statistics, Causes and What to Do

TL;DR — Fatty liver disease in Canada, in one paragraph

Fatty liver disease (non‑alcoholic or metabolic dysfunction‑associated) affects millions of Canadians — commonly quoted as more than 7 million — and is strongly linked to obesity, insulin resistance and type 2 diabetes. Most people have simple steatosis with little short‑term liver damage, but a significant minority progress to inflammation (NASH/MASH), fibrosis, cirrhosis or liver cancer. Early detection through primary care, lifestyle intervention (weight loss, diet, exercise) and targeted medical care where needed are the pillars of reducing community burden. ([liver.ca](https://liver.ca/wp-content/uploads/2018/06/CLF-Annual-Report-2017-EN-June-7-Final.pdf?utm_source=openai))

Scope in Canada — the "7 million" figure explained

Headlines that "7 million Canadians have fatty liver disease" come from national estimates cited by the Canadian Liver Foundation and earlier Canadian modelling studies that analysed obesity, diabetes and population data to estimate prevalence. The Canadian Liver Foundation's materials reported that over 7,000,000 people in Canada are affected by non‑alcoholic fatty liver disease (NAFLD). ([liver.ca](https://liver.ca/wp-content/uploads/2018/06/CLF-Annual-Report-2017-EN-June-7-Final.pdf?utm_source=openai))

Causes and risk factors — the Canadian context

Fat accumulates in the liver when metabolic processes that normally handle fat and sugar become overwhelmed. Primary drivers include:

• Overweight and obesity (central adiposity). Canada has seen rising adult overweight/obesity rates: recent Canadian Health Measures Survey results report that about two‑thirds (68%) of adults aged 18–79 were overweight or living with obesity during 2022–2024, an increase from pre‑pandemic levels. This trend strongly drives fatty liver prevalence. ([www150.statcan.gc.ca](https://www150.statcan.gc.ca/n1/daily-quotidien/251002/dq251002b-eng.pdf?utm_source=openai))
• Type 2 diabetes and insulin resistance — people with diabetes have markedly higher rates of fatty liver and of progressive liver fibrosis. Snapshot data on diabetes in Canada show continued high prevalence and important comorbidity. ([canada.ca](https://www.canada.ca/en/public-health/services/publications/diseases-conditions/snapshot-diabetes-canada-2023.html?utm_source=openai))
• Dyslipidaemia, hypertension and the metabolic syndrome cluster — the same cardiometabolic risk factors that increase heart disease risk in Canadians also raise fatty liver risk. (Heart & Stroke Foundation guidance highlights the overlap between cardiometabolic risk and liver disease.)
• Age, ethnicity and genetics — rates vary by ancestry and increase with age; certain ethnic groups may develop fatty liver at lower BMI thresholds. Canadian studies and guidelines recognise these nuances. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC7286622/?utm_source=openai))
• Medications and alcohol — while NAFLD is by definition non‑alcoholic, alcohol intake and some medications can worsen liver health and should be discussed with clinicians.

Symptoms — when to see your family doctor

Fatty liver is frequently asymptomatic. When present, symptoms are non‑specific: fatigue, discomfort or a vague ache in the right upper abdomen, or nonspecific decreased energy. Because symptoms are unreliable, high‑risk Canadians (those with obesity, type 2 diabetes, metabolic syndrome or persistently abnormal liver enzymes) should be assessed by primary care.

If you notice jaundice (yellowing of the eyes or skin), marked abdominal swelling, unexplained weight loss, persistent fevers, or dark urine, seek urgent care — these signs suggest advanced liver disease or another emergent issue.

How fatty liver is diagnosed in Canada

Diagnosis typically follows a stepwise pathway led by primary care:

1. History and physical exam to rule out other liver diseases and assess alcohol intake.
2. Blood tests — liver enzymes (ALT, AST), platelets, albumin, fasting glucose or HbA1c (mmol/L units for glucose reporting in Canada are used in many labs), and lipid panels. Mild enzyme elevations are common but normal enzymes do not exclude fatty liver.
3. Imaging — liver ultrasound is widely used as a first‑line test to detect steatosis; it is available through provincial imaging services (OHIP in Ontario, MSP in BC, Alberta Health Services in Alberta, etc.). More advanced centres use transient elastography (FibroScan) to assess liver stiffness (a proxy for fibrosis). Provincial pathways increasingly incorporate FibroScan and non‑invasive fibrosis scoring. ([albertahealthservices.ca](https://www.albertahealthservices.ca/assets/about/scn/ahs-scn-dh-pathway-nafld.pdf?utm_source=openai))
4. Non‑invasive fibrosis scores — FIB‑4, NAFLD Fibrosis Score and other calculators are recommended as initial triage tools to decide who needs hepatology referral. CASL and Diabetes Canada endorse such stepwise approaches for case finding and fibrosis risk stratification. ([hepatology.ca](https://hepatology.ca/2026/06/16/casl-advocacy-letter-on-importance-of-ast-in-non-invasive-screening-strategies-for-masld-related-liver-fibrosis/?utm_source=openai))
5. Liver biopsy — reserved for unclear cases or when advanced disease is suspected; biopsy remains the reference standard but is not required in most routine patients.

Treatment and long‑term management

There are currently no Health Canada‑approved drugs that reverse all forms of fatty liver disease for broad use; treatment focuses on addressing root causes and preventing progression. Major pillars of care:

• Weight loss: A sustained weight loss of 5–10% of body weight often reduces liver fat; greater weight loss (7–10% or more) may reverse inflammation and early fibrosis in some people. Clinically supervised weight‑management programmes, dietitians and, where appropriate, bariatric surgery are effective options. Canadian primary care and provincial programmes (referral pathways differ by province) can support this. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC7286622/?utm_source=openai))
• Nutrition: Focus on whole foods, reduced processed carbohydrates and added sugars, more vegetables, lean proteins and healthy fats. In the Canadian grocery context, small practical swaps (for example, choosing wholegrain options available at Loblaws, Sobeys or Metro, reducing sugary beverages) help reduce liver fat. Evidence supports Mediterranean‑style patterns and reduced ultra‑processed food consumption.
• Physical activity: Regular moderate‑to‑vigorous activity (150–300 minutes/week) plus resistance training improves insulin sensitivity and liver fat independent of weight loss.
• Control cardiometabolic risk: Treat diabetes (aim for individualized HbA1c targets), hypertension and dyslipidaemia — many cardiometabolic therapies benefit liver outcomes indirectly. Recent Canadian diabetes guidance and CanNASH collaborations emphasise cross‑discipline care. ([canada.ca](https://www.canada.ca/en/public-health/services/publications/diseases-conditions/snapshot-diabetes-canada-2023.html?utm_source=openai))
• Specialist care: Hepatology referral is indicated for suspected advanced fibrosis, unexplained liver abnormalities or when targeted pharmacologic therapies (clinical trials or off‑label options) are under consideration. Referral criteria and wait times depend on provincial systems (OHIP, MSP, etc.).

Emerging therapeutics are under study globally; some will go through Health Canada reviews and CADTH reimbursement processes before becoming widely available in Canada. Until then, lifestyle and comorbidity management are the proven mainstays. ([cda-amc.ca](https://www.cda-amc.ca/sites/default/files/DRR/2025/SR0865_elafibranor_Clinician_Patient_Input.pdf?utm_source=openai))

Prevention strategies for Canadians

Population‑level prevention requires addressing the upstream determinants of obesity and diabetes: healthy food access, physical activity environments, and targeted supports for higher‑risk communities (including Indigenous peoples, who face disproportionate burdens of cardiometabolic disease). Practical, individual prevention steps include:

• Keep active year‑round — adapt for Canadian seasons (winter walking, indoor community centre programs, home resistance workouts).
• Choose minimally processed foods; shop smart at national chains like Loblaws, Sobeys or Metro where seasonal produce and wholegrain options are available.
• Limit sugary drinks and ultra‑processed snacks; read Nutrition Facts tables and watch portion sizes.
• Get regular primary‑care checkups — especially if you have diabetes, high blood pressure or obesity; early identification allows simple interventions to be effective.

Care pathways and provincial health coverage

Canada's publicly funded health system covers physician visits, most hospital care and provincially funded imaging and specialist services under respective plans (example: OHIP in Ontario, MSP in British Columbia, Alberta Health Services). The exact referral pathway for liver imaging (ultrasound versus FibroScan) and specialist hepatology varies by province and local health authority. Many provinces now implement primary‑care‑led case‑finding using FIB‑4 followed by FibroScan for intermediate‑risk people to prioritise hepatology referrals. ([albertahealthservices.ca](https://www.albertahealthservices.ca/assets/about/scn/ahs-scn-dh-pathway-nafld.pdf?utm_source=openai))

If you live in Canada and are concerned about liver health, start with your family physician or walk‑in clinic (covered by provincial plans). They will advise on blood tests, imaging referrals and whether specialist care is required. For people in remote communities or territories, virtual care and provincial outreach programmes are increasingly used to improve access.

Public‑health impact & projections

Fatty liver disease is not only a liver problem: it sits at the intersection of diabetes, cardiovascular disease and cancer, amplifying overall healthcare needs. Canadian modelling projected rising numbers of NAFLD and NASH cases to 2030 if current obesity trends continue, with corresponding increases in cirrhosis, liver cancer and liver‑related healthcare use. This has implications for hospital admissions, transplant programs and provincial budgets. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC7286622/?utm_source=openai))

Addressing fatty liver therefore needs integrated public‑health action (healthy food environments, physical activity promotion, diabetes prevention) alongside clinical pathways for early detection and management. Initiatives that reduce obesity and improve cardiometabolic care will lower fatty liver incidence and progression. ([www150.statcan.gc.ca](https://www150.statcan.gc.ca/n1/daily-quotidien/251002/dq251002b-eng.pdf?utm_source=openai))

Canadian resources and references

Key Canadian organisations and resources:

• Canadian Liver Foundation — awareness, patient resources and data. ([liver.ca](https://liver.ca/wp-content/uploads/2018/06/CLF-Annual-Report-2017-EN-June-7-Final.pdf?utm_source=openai))
• Canadian Association for the Study of the Liver (CASL / hepatology.ca) — clinical guidance and advocacy. ([hepatology.ca](https://hepatology.ca/?utm_source=openai))
• CanNASH / Canadian NASH Network — research, workshop reports and care considerations. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC9231423/?utm_source=openai))
• Statistics Canada — national data on obesity and health measures. ([www150.statcan.gc.ca](https://www150.statcan.gc.ca/n1/daily-quotidien/251002/dq251002b-eng.pdf?utm_source=openai))
• Public Health Agency of Canada / Diabetes Canada — diabetes and cardiometabolic surveillance. ([canada.ca](https://www.canada.ca/en/public-health/services/publications/diseases-conditions/snapshot-diabetes-canada-2023.html?utm_source=openai))
• Provincial health authorities (OHIP, MSP, Alberta Health Services) — local referral pathways and imaging access. ([albertahealthservices.ca](https://www.albertahealthservices.ca/assets/about/scn/ahs-scn-dh-pathway-nafld.pdf?utm_source=openai))

Selected scientific references

1. Canadian Liver Foundation — Annual report and NAFLD facts (cited national 7 million figure). ([liver.ca](https://liver.ca/wp-content/uploads/2018/06/CLF-Annual-Report-2017-EN-June-7-Final.pdf?utm_source=openai))
2. Younossi ZM et al. Burden of nonalcoholic fatty liver disease in Canada, 2019–2030: a modelling study (CMAJ Open). ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC7286622/?utm_source=openai))
3. CanNASH workshop insights: Current considerations for clinical management of NAFLD (CanNASH). ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC9231423/?utm_source=openai))
4. Global prevalence systematic reviews/meta‑analyses on NAFLD (J Hepatol / PMC). ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10029957/?utm_source=openai))
5. Statistics Canada — Canadian Health Measures Survey: overweight and obesity trends 2022–2024. ([www150.statcan.gc.ca](https://www150.statcan.gc.ca/n1/daily-quotidien/251002/dq251002b-eng.pdf?utm_source=openai))
6. Public Health Agency of Canada — Snapshot of Diabetes in Canada. ([canada.ca](https://www.canada.ca/en/public-health/services/publications/diseases-conditions/snapshot-diabetes-canada-2023.html?utm_source=openai))
7. CIHI — Hospital stays and health system indicators related to liver disease and chronic disease burden. ([cihi.ca](https://www.cihi.ca/en/hospital-stays-in-canada-2022-2023?utm_source=openai))
8. Alberta Health Services — NAFLD care pathway and provincial guidance examples. ([albertahealthservices.ca](https://www.albertahealthservices.ca/assets/about/scn/ahs-scn-dh-pathway-nafld.pdf?utm_source=openai))

FAQ

Q: Is fatty liver reversible?

A: Early fatty liver (steatosis) is often reversible with sustained lifestyle changes, especially weight loss and improved metabolic control. Advanced fibrosis and cirrhosis may not be fully reversible, but progression can often be slowed or halted with appropriate care. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC7286622/?utm_source=openai))

Q: How common is fatty liver in people with type 2 diabetes?

A: People with type 2 diabetes have substantially higher rates of fatty liver and are at greater risk of fibrosis; diabetes care programmes in Canada emphasise liver risk assessment as part of comprehensive management. ([canada.ca](https://www.canada.ca/en/public-health/services/publications/diseases-conditions/snapshot-diabetes-canada-2023.html?utm_source=openai))

Q: Should I get a liver ultrasound if my ALT is normal?

A: Normal liver enzymes do not rule out fatty liver. If you have risk factors (obesity, diabetes, metabolic syndrome), talk to your family physician about assessment and possible imaging — many primary‑care pathways use non‑invasive scores plus targeted imaging. ([hepatology.ca](https://hepatology.ca/2026/06/16/casl-advocacy-letter-on-importance-of-ast-in-non-invasive-screening-strategies-for-masld-related-liver-fibrosis/?utm_source=openai))

Q: Are there medications approved in Canada specifically for NAFLD/NASH?

A: As of the most recent Canadian guidance, there are no widely approved, reimbursed drugs that cure NAFLD for all patients; several therapies are in clinical trials and Health Canada/CADTH reviews will guide future access. Management today focuses on lifestyle and treating comorbidities. ([cda-amc.ca](https://www.cda-amc.ca/sites/default/files/DRR/2025/SR0865_elafibranor_Clinician_Patient_Input.pdf?utm_source=openai))

Q: How does fatty liver affect heart disease risk?

A: Fatty liver is part of the cardiometabolic risk spectrum and is associated with higher risk of cardiovascular disease — the leading cause of death in people with NAFLD. Comprehensive risk factor control (blood pressure, lipids, glucose, smoking cessation) reduces overall vascular risk.

Q: Can children in Canada get fatty liver?

A: Yes. Pediatric fatty liver is increasingly recognised in Canadian children with obesity. Early prevention, family‑centred nutrition and activity strategies are important. The Canadian Liver Foundation and paediatric clinics provide resources for families. ([liver.ca](https://liver.ca/wp-content/uploads/2018/06/CLF-Annual-Report-2017-EN-June-7-Final.pdf?utm_source=openai))

Medical disclaimer

This article is for informational purposes only and does not constitute medical advice. It does not replace assessment by a qualified healthcare professional. For personal medical concerns or symptoms, please consult your family doctor or local provincial healthcare services (OHIP, MSP, Alberta Health Services, etc.).